Tag: Perampanel

For approximately one-third of epilepsy patients, seizures remain uncontrolled by conventional medications. A newer antiepileptic drug (AED) is designed to address this challenge, offering novel mechanisms of action and often-improved tolerability to provide better seizure control and quality of life for those with refractory epilepsy.

Approximately one-third of individuals with epilepsy do not achieve seizure control with older, traditional medications. This has driven the development of numerous newer drugs used for management of epilepsy, expanding treatment options for both drug-resistant and newly diagnosed patients. These newer antiepileptic drugs (AEDs) often offer better tolerability, more focused mechanisms, and fewer drug interactions.

While about 70% of patients with epilepsy achieve seizure control with one to three antiseizure medications (ASMs), many still experience adverse effects or have drug-resistant epilepsy, necessitating the development of newer treatments. The latest therapies, known as new generation antiseizure drugs, offer unique mechanisms and improved safety profiles to address these challenges.

Over a third of people with epilepsy experience uncontrolled seizures, a challenge often complicated by a complex medication schedule. Simplifying treatment is crucial, which is why a once daily seizure medication can be a significant benefit for improving patient adherence and seizure control.